| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a0d57d0807d6cf330fa6c6966f05837 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q19-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-892
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 |
| filingDate |
2015-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2766be92fa29c5c334005e108e07a1bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39559867875a46584ff95a7e5ef5ccb1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab5c9432194d4a867a3c8f7502a68d2c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40bc9b30aa3254c7a2399d4b5a2a04a0 |
| publicationDate |
2015-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2015134951-A1 |
| titleOfInvention |
Amnion derived therapeutic compositions and methods of use |
| abstract |
A therapeutic composition may include a fluid component and/or a matrix component derived from amnion. A matrix component may be an amniotic membrane that is free of chorion. A fluid component may be a fluid having a concentration of stem cells, such as amniotic stem cells, and/or micronized amniotic membrane particles. A preferred fluid component includes micronized amniotic membrane particles dispersed in an amniotic stem cell concentrated fluid. An amniotic stem cell concentrated fluid has at least 0.1 x 10 6 amniotic stem cells per milliliter of fluid or composition, A therapeutic composite may be used to treat any number of heart related conditions through topical application, injection or through introduction intravenously. A matrix component may be located on a treatment location and a fluid component may be subsequently introduced to the matrix component. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11369643-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3242672-A4 |
| priorityDate |
2014-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |